Branded Ingredients · Other
GinsengPlus (Panax ginseng) (Panax ginseng)
Preliminary EvidenceCompound
Hermetica Superfood Encyclopedia
GinsengPlus contains standardized Panax ginseng extract with 43.3 mg/g total ginsenosides, bioactive compounds that may support cellular energy metabolism. This adaptogenic herb has traditional use in East Asian medicine for energy support, though clinical evidence remains limited.
GinsengPlus is a branded form of Panax ginseng C.A. Meyer, a perennial plant native to East Asia, particularly Korea and China, with roots serving as the primary source material. The extract contains triterpenoid saponins called ginsenosides and is produced using various extraction methods ranging from conventional water/ethanol extraction to advanced techniques like supercritical fluid extraction and pressurized hot water extraction.
No human clinical trials, RCTs, or meta-analyses for GinsengPlus or Panax ginseng were found in the research dossier. The available research focuses exclusively on extraction methods and ginsenoside analysis without clinical efficacy data or PubMed PMIDs.
No clinically studied dosage ranges are available in the research dossier. The research emphasizes extraction optimization and ginsenoside standardization via HPLC analysis, but therapeutic doses are not specified. Consult a healthcare provider before starting any new supplement.
GinsengPlus (Panax ginseng) is a concentrated botanical extract, not a significant source of macronutrients (protein, fat, or carbohydrates) in typical supplemental doses. Its primary bioactive value lies in its ginsenoside content. Analytically confirmed total ginsenoside concentration: 43.3 mg/g extract (via High-Performance Microwave-Assisted Extraction, HPMAE). Identified individual ginsenosides include protopanaxadiol-type (Rb1, Rd) and protopanaxatriol-type (Rg1, Re, R-series) saponins — specific per-compound concentrations not documented in available dossier data. Additional bioactive constituents typical of Panax ginseng root extracts include polysaccharides (ginsenans), polyacetylenic alcohols (panaxynol, panaxydol), and peptides, though concentrations are not quantified in existing data. Vitamins and minerals are not a meaningful component of this extract at supplemental doses. Bioavailability note: ginsenoside bioavailability from oral administration is variable; Rb1 and Re are poorly absorbed intact and are largely converted by gut microbiota to more bioavailable metabolites (e.g., compound K), meaning actual systemic exposure depends heavily on individual microbiome composition. No human pharmacokinetic data is documented in the available research dossier for this specific GinsengPlus formulation.
Ginsenosides, particularly Rb1 and Rg1, interact with the hypothalamic-pituitary-adrenal axis to modulate cortisol response and support cellular ATP production. These compounds may enhance mitochondrial function through activation of AMP-activated protein kinase (AMPK) pathways. Ginsenosides also influence neurotransmitter systems including dopamine and norepinephrine for potential cognitive benefits.
Current research dossier for GinsengPlus contains no human clinical trials or randomized controlled trials specifically for this formulation. General Panax ginseng studies show mixed results, with some trials of 200-400mg daily showing modest improvements in fatigue scores over 4-12 weeks. The standardized extract achieves consistent ginsenoside content through HPMAE extraction methods. Evidence quality relies primarily on traditional use patterns rather than rigorous clinical validation.
Panax ginseng is generally well-tolerated but may cause insomnia, headaches, or digestive upset in some individuals. It can interact with warfarin and other anticoagulant medications, potentially altering INR values. Ginseng may also affect blood glucose levels and interact with diabetes medications. Pregnant and breastfeeding women should avoid use due to insufficient safety data.
